	US 11,969,460 B2
	Methods and compositions for treating decreased cognitive ability
Andrew Alistair Butler, St. Louis, MO (US); Susan Farr, St. Louis, MO (US); and Clemence Girardet, Paris (FR)
Assigned to Saint Louis University, St. Louis, MO (US); and U.S. Department of Veternas Affairs, Washington, DC (US)
Appl. No. 17/054,740
Filed by Saint Louis University, St. Louis, MO (US); and U.S. DEPARTMENT OF VETERANS' AFFAIRS, Washington, DC (US)
PCT Filed Jun. 4, 2019, PCT No. PCT/US2019/035428 § 371(c)(1), (2) Date Nov. 11, 2020, PCT Pub. No. WO2019/236603, PCT Pub. Date Dec. 12, 2019.
Claims priority of provisional application 62/682,717, filed on Jun. 8, 2018.
Prior Publication US 2021/0252108 A1, Aug. 19, 2021
Int. Cl. A61K 38/22 (2006.01); A61P 25/28 (2006.01); A61K 48/00 (2006.01)

CPC A61K 38/22 (2013.01) [A61P 25/28 (2018.01); A61K 48/00 (2013.01)]

11 Claims

1. A method of treating a subject in need thereof medically diagnosed with age-related cognitive decline and a decreased level of adropin compared to a previous level of adropin in the subject, the method comprising administering to the subject an effective amount of the adropin amino acid sequence of SEQ ID NO: 1 or the adropin34-76 peptide fragment amino acid sequence of SEQ ID NO: 2, wherein the effective amount is sufficient to delay or not allow further progression of age-related cognitive decline as determined by a medically diagnosing professional on a subject by subject basis as to the subject in need thereof; by measuring the before and after treatment results of any standard cognitive functioning test that specifically tests for age-related cognitive decline.